Quick Answer
Vistagen Therapeutics, Inc. reported Total Revenue of $1.09 million for the year ending 2021.
- This data is from Vistagen Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 29, 2021.
- XBRL data for this metric is available from 2011 to 2021 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $733.9 thousand | Q3 2010: $399.6 thousand | Q4 2010: $584.8 thousand | Q2 2011: $555.0 thousand | Q3 2011: $316.0 thousand | Q4 2011: $2.0 thousand | Q1 2012: $469.0 thousand | Q2 2012: $200.4 thousand | Q4 2015: $0.00 | Q2 2016: $0.00 | Q3 2016: $0.00 | Q4 2016: $1.25 million | Q1 2017: $0.00 | Q4 2017: $0.00 | Q2 2019: $0.00 | Q3 2019: $0.00 | Q4 2019: $0.00 | Q1 2020: $0.00 | Q2 2020: $0.00 | Q3 2020: $334.0 thousand | Q4 2020: $314.0 thousand | Q1 2021: $442.0 thousand | Q2 2021: $354.1 thousand.
- Over the full 8 years of available data (2011 to 2021), Vistagen Therapeutics, Inc.'s Total Revenue has declined by 47.4%.
- Historical annual values: Fiscal year 2021: $1.09 million | Fiscal year 2020: $0.00 | Fiscal year 2018: $0.00 | Fiscal year 2017: $1.25 million | Fiscal year 2016: $0.00 | Fiscal year 2013: $200.4 thousand | Fiscal year 2012: $1.34 million | Fiscal year 2011: $2.07 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: